Outcomes after radiation therapy for T2N0/stage II glottic squamous cell carcinoma

dc.contributor.authorAl-Feghali, Karine A.
dc.contributor.authorYoussef, Bassem Y.
dc.contributor.authorMohamed, Abdallah Sherif Radwan
dc.contributor.authorHilal, Lara
dc.contributor.authorSmith, Blaine D.
dc.contributor.authorAbu-Gheida, Ibrahim H.
dc.contributor.authorFarha, Georges
dc.contributor.authorGunn, G. Brandon
dc.contributor.authorPhan, Jack
dc.contributor.authorLewin, Jan S.
dc.contributor.authorThekdi, Apurva A.
dc.contributor.authorMorrison, William H.
dc.contributor.authorGarden, Adam Seth
dc.contributor.authorFuller, Clifton David
dc.contributor.authorRosenthal, David I.
dc.contributor.departmentRadiation Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:12:23Z
dc.date.available2025-01-24T12:12:23Z
dc.date.issued2020
dc.description.abstractBackground: We report outcomes for patients with T2N0M0 glottic squamous cell carcinoma (SCC) treated with radiation therapy (RT). Methods: Patients who received definitive RT for T2 glottic SCC from 2000 through 2013 were retrospectively reviewed. Results: One hundred and thirteen patients were analyzed (median follow-up time 91 months; 85 patients received three-dimensional conformal radiotherapy [3D-CRT] and 28 received intensity-modulated radiation therapy [IMRT]). Fractionation was conventional (58%) or altered (42%); 20 patients (18%) received concurrent chemotherapy. Five-year local control was 83% for the 3D-CRT vs 81% for the IMRT group (P =.76). The ultimate locoregional control at 5 years was 100% for IMRT vs 91% for 3D-CRT (P =.1). The 5-year overall survival (OS) was 78% for 3D-CRT vs 81% for IMRT (P =.83). On multivariate analysis, younger age was the only independent predictor of improved OS (P =.0002). Conclusions: Oncologic and survival outcomes were excellent for patients with T2N0 glottic cancer. Patients treated with IMRT and 3D-CRT had no statistically significant differences in all investigated endpoints. © 2020 Wiley Periodicals, Inc.
dc.identifier.doihttps://doi.org/10.1002/hed.26308
dc.identifier.eid2-s2.0-85085699955
dc.identifier.pmid32484591
dc.identifier.urihttp://hdl.handle.net/10938/32748
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc.
dc.relation.ispartofHead and Neck
dc.sourceScopus
dc.subjectLarynx
dc.subjectOutcomes
dc.subjectRadiotherapy
dc.subjectSurvival
dc.subjectT2
dc.subjectAntineoplastic agent
dc.subjectRadiosensitizing agent
dc.subjectAdult
dc.subjectAged
dc.subjectArticle
dc.subjectCancer chemotherapy
dc.subjectCancer radiotherapy
dc.subjectCancer staging
dc.subjectCancer survival
dc.subjectConformal radiotherapy
dc.subjectFemale
dc.subjectFollow up
dc.subjectHoarseness
dc.subjectHuman
dc.subjectIntensity modulated radiation therapy
dc.subjectLaryngectomy
dc.subjectLarynx squamous cell carcinoma
dc.subjectMajor clinical study
dc.subjectMale
dc.subjectMedical record review
dc.subjectOutcome assessment
dc.subjectOverall survival
dc.subjectPriority journal
dc.subjectRadiation dermatitis
dc.subjectRadiation dose fractionation
dc.subjectRadiotherapy dosage
dc.subjectRetrospective study
dc.subjectVocal cord disorder
dc.titleOutcomes after radiation therapy for T2N0/stage II glottic squamous cell carcinoma
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2020-6533.pdf
Size:
1.03 MB
Format:
Adobe Portable Document Format